ARS CRO submitted a CTA for approval of two comparative studies of pharmacokinetics and bioequivalence of Lamivudine and Lamivudine + Zidovudine combination to the Russian Ministry of Health. The studies are the result of the repeat business with the leading Indian pharmaceutical company that is among the largest manufacturers of specialty soft gelatin capsules in the world.